Amanda Hays has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development

    by Carmen Fernández-Metzler, Karen J. Quadrini, Lakshmi Amaravadi, Stephanie Cape, Jennifer Green, Amanda Hays, Jurre J. Kamphorst, Sreenivas Laxmanan, Alok Pandey, Xiazi Qiu, et al.

    Pharmacodynamic (PD) biomarkers provide crucial insights into a drug's mechanism of action (MoA) and efficacy by measuring its effects on biological targets within an organism. PD biomarkers can be proximal (e.g. receptor occupancy, enzyme inhibition) or distal (e.g. downstream pathway modulation) to the biological target. In drug development, PD biomarkers are essential for monitoring patient response, assessing therapeutic efficacy, optimizing dosage strategies, and streamlining the drug development process by informing go/no-go decisions. In personalized medicine, PD biomarkers enable tailored treatments based on individual responses, enhancing both effectiveness and safety. Sound bioanalytical strategies and rigorous assay validation practices are key for successful integration of PD biomarkers into clinical trials. This paper outlines the bioanalytical and assay considerations for developing and validating informative PD biomarker assays and their use in drug development.


  • Open Access

    Why is Biomarker Assay Validation Different from that of Pharmacokinetic Assays?

    by Yan G. Ni, Lauren F. Stevenson, Lakshmi Amaravadi, Carmen Fernández-Metzler, Lindsay King, Steven P. Piccoli, Amanda Hays, Dhiman Ghosh, Sarah Mitchell Bean, Stephanie Cape, et al.


  • Open Access

    Technical Considerations of Pharmacokinetic Assays for LNP-mRNA Drug Products by RT-qPCR

    by Jason Pennucci, Amanda Hays, Wendy Adamowicz, Mitra Azadeh, Mohamed Benhammadi, Enric Bertran Portabella, MingLai Cheng, Kelly Colletti, Sanjay L. Dholakiya, Rajitha Doddareddy, et al.

    Lipid nanoparticle-messenger RNA (LNP-mRNA) drug products are a growing class of drug modalities. The unique composition of these drug products requires multiple measurements to account for the different components of these drug modalities. Pharmacokinetic (PK) measurements include measurement of the encapsulated mRNA and components of the LNP in circulation to understand the effectiveness of the therapeutic mRNA. The PK measurements can utilize many different platforms including PCR. Current regulatory guidance documents for bioanalytical method validation are specific to ligand binding and chromatographic assay methods and difficult to interpret for use with molecular workflows. The purpose of this paper is to provide information on considerations for validation of regulated reverse transcription quantitative PCR (RT-qPCR) assays that are used to support the pharmacokinetic analysis of LNP-mRNA drug products. Graphical Abstract


  • Open Access

    Development of a validated novel bead extraction method for the detection of anti-PEG antibodies in human serum

    by William T. Williams, Kathryn Lindley, Hong Liao, Lynn Kamen, Michelle Miller, Amanda Hays, Jeffrey Sailstad

    Polyethylene glycol (PEG) is used in many applications including drug development. Due to exposure to environmental products, there is a high prevalence of preexisting anti-PEG antibodies in the global human population. The presence of anti-PEG antibodies is a concern for potentially reducing the efficacy of therapeutics after administration and represents a risk of safety events after exposure to PEGylated drug products. We developed and validated a creative and sensitive method for the detection of anti-PEG antibodies in human serum to support clinical programs for PEGylated drugs. In this method, biotin-PEG streptavidin beads were used to extract anti-PEG antibodies from human serum for analysis in an anti-PEG ELISA assay. The same serum sample was analyzed in an anti-drug antibody assay. The anti-PEG antibody assay was validated with a screening cut point of 1.41 normalized signal, confirmatory cut point of 32.2% inhibition, sensitivity of 7.81 ng/mL and sufficient reproducibility, selectivity, and drug tolerance in accordance with the FDA 2019 Immunogenicity guidance. This method of removal of anti-PEG antibodies enables the use of a single sample to detect anti-drug and anti-PEG antibodies to support drug development programs.


  • Top Cited Papers
    Open Access

    Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development

    by Amanda Hays, Mark Wissel, Kelly Colletti, Russell Soon, Mitra Azadeh, Justin Smith, Rajitha Doddareddy, Melanie Chalfant, Wendy Adamowicz, Swarna Suba Ramaswamy, et al.

    : The emerging use of qPCR and dPCR in regulated bioanalysis and absence of regulatory guidance on assay validations for these platforms has resulted in discussions on lack of harmonization on assay design and appropriate acceptance criteria for these assays. Both qPCR and dPCR are extensively used to answer bioanalytical questions for novel modalities such as cell and gene therapies. Following cross-industry conversations on the lack of information and guidelines for these assays, an American Association of Pharmaceutical Scientists working group was formed to address these gaps by bringing together 37 industry experts from 24 organizations to discuss best practices to gain a better understanding in the industry and facilitate filings to health authorities. Herein, this team provides considerations on assay design, development, and validation testing for PCR assays that are used in cell and gene therapies including (1) biodistribution; (2) transgene expression; (3) viral shedding; (4) and persistence or cellular kinetics of cell therapies. Graphical Abstract


  • Open Access

    Validation of Anti-Adeno Associated Virus Serotype rh10 (AAVrh.10) Total and Neutralizing Antibody Immunogenicity Assays

    by Elizabeth Butala-Flores, Thien Nguyen, Nithya Selvan, Luke Armstrong, Michelle Miller, Lynn Kamen, Todd Lester, Roman Wernyj, Richie Khanna, Jim McNally, et al.

    Immunogenicity assessment of Adeno-Associated Virus (AAV) vectors is a critical part of gene therapy drug development. Whether the assays are used for inclusion/exclusion criteria or to monitor the safety and efficacy of the gene therapy, they are critical bioanalytical assessments. While total anti-AAV assays are perceived as easier to develop and implement than neutralizing anti-AAV assays, the gene therapy field is still nascent, and it is not yet clear which of the assays should be implemented at what stage of drug development. Recently AAVrh.10 has gained interest for use in gene therapies targeting cardiac, neurological, and other diseases due to its enhanced transduction efficiency. There is limited information on anti-AAVrh.10 antibodies and their clinical impact; thus, the information presented herein documents the validation of both a total antibody assay (TAb) and a neutralizing antibody (NAb) assay for anti-AAVrh.10 antibodies. In this manuscript, the validation was performed in accordance with the 2019 FDA immunogenicity guidance with additional evaluations to comply with CLIA where applicable. The AAVrh.10 TAb and NAb assays were compared in terms of sensitivity, drug tolerance, and precision, along with a concordance analysis using the same individual serum samples. This comparison gave insight into the utility of each format as a screening assay for inclusion into clinical studies.


  • Bioanalytical Assays: Toxicokinetic

    by Marianne Scheel Fjording, Amanda Hays, Ahmed Kousba

  • Open Access

    Bioanalytical Assay Strategies and Considerations for Measuring Cellular Kinetics

    by Amanda Hays, Jennifer Durham, Bryan Gullick, Nathan Rudemiller, Thomas Schneider

    A vast evolution of drug modalities has occurred over the last several decades. Novel modalities such as cell and gene therapies have proven to be efficacious for numerous clinical indications–primarily in rare disease and immune oncology. Because of this success, drug developers are heavily investing in these novel modalities. Given the complexity of these therapeutics, a variety of bioanalytical techniques are employed to fully characterize the pharmacokinetics of these therapies in clinical studies. Industry trends indicate that quantitative PCR (qPCR) and multiparameter flow cytometry are both valuable in determining the pharmacokinetics, i.e. cellular kinetics, of cell therapies. This manuscript will evaluate the pros and cons of both techniques and highlight regulatory guidance on assays for measuring cellular kinetics. Moreover, common considerations when developing these assays will be addressed.


  • Is Incurred Sample Reanalysis (ISR) Applicable in Biomarker Assays?

    by Amanda Hays, Lakshmi Amaravadi, Carmen Fernandez-Metzler, Lindsay King, Joel Mathews, Yan Ni, Karen Quadrini, Chunyan Tinder, Faye Vazvaei, Jianing Zeng